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Background. Fructose metabolism is an unregulated metabolic pathway and excessive fructose consumption is known to activate
ROS.HO-1 is a potent antioxidant gene that plays a key role in decreasingROS and isoprostanes.We examinedwhether the fructose-
mediated increase in adipocyte dysfunction involves an increase in isoprostanes and that pharmacological induction ofHO-1 would
decrease both isoprostane levels and adipogenesis. Methods and Results. We examined the effect of fructose, on adipogenesis in
human MSCs in the presence and absence of CoPP, an inducer of HO-1. Fructose increased adipogenesis and the number of large
lipid droplets while decreasing the number of small lipid droplets (𝑃 < 0.05). Levels of heme and isoprostane in fructose treated
MSC-derived adipocytes were increased. CoPP reversed these effects andmarkedly increasedHO-1 and theWnt signaling pathway.
The high fructose diet increased heme levels in adipose tissue and increased circulating isoprostane levels (𝑃 < 0.05 versus control).
Fructose diets decreasedHO-1 and adiponectin levels in adipose tissue. Induction ofHO-1 byCoPP decreased isoprostane synthesis
(𝑃 < 0.05 versus fructose).Conclusion. Fructose treatment resulted in increased isoprostane production and adipocyte dysfunction,
which was reversed by the increased expression of HO-1.
1. Introduction
Over the past several decades the use of fructose, as a
sweetener, has emerged in processed foods, soft drinks, and
an assortment of desserts [1–3]. Fructose has been linked
to the development and exacerbation of centripetal obesity
and metabolic syndrome, in both animals and humans [3].
In addition, excessive fructose consumption (>50 g/d) is
involved in the development of metabolic imbalance and
diabetes, independent of caloric restriction and weight gain
[2, 4]. Sucrose, commonly found in table sugar, is a disaccha-
ride comprising equimolar amounts of fructose and glucose
and is the worldwide primary source for dietary fructose [1].
In light of the correlation between fructose and obesity, it is
imperative to examine the pathogenesis by which fructose
may lead to metabolic syndrome and adiposity.
Fructose is absorbed by the small intestine via passage
through GLUT 5 transporters and is metabolized through
the glycolytic pathway [1, 5]. Excessive fructose intake is
associated with elevated levels of inflammatory mediators
and reactive oxygen species (ROS), thereby contributing to
the onset of metabolic syndrome and obesity [6]. Obesity is
associated with oxidative stress, increased levels of ROS, and
an increase in free heme, a known prooxidant [7, 8].
During oxidative stress, heme is released from cells and
tissue and contributes to the growing “free heme pool.”
Free heme is a potent prooxidant and increases ROS lev-
els [8–11]. Elevated levels of heme are toxic to the body
and catalyze oxidative damage to cells, tissues, and organs.
Obesity and oxidative stress increase cellular heme and the
heme-mediated increased generation of isoprostanes [8, 10,
11]. Isoprostanes are prostaglandin-like compounds formed
in vivo from the free radical-catalyzed peroxidation of the
essential fatty acid, arachidonic acid [12]. These nonclassical
eicosanoids have strong biological activity as inflammatory
mediators [13] and are recognized as markers of lipid perox-
idation in both animal and human models of oxidative stress
[11, 14, 15]. In obese patients, urine isoprostane levels increase
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with increasing BMI in both male and female subjects
[16]. Plasma concentration of isoprostane increases during
acute fructose loading [17]. Fructose-induced oxidative stress
and insulin resistance in humans are prevented by grape
polyphenols [18].
Excessive fructose consumption leads to the elevation
of ROS [19] and may lead to increased lipid peroxidation,
altered metabolic homeostasis, and hypertrophic adipogen-
esis. Adipogenesis begins with the commitment of MSCs to
the adipocyte lineage, followed by terminal differentiation
of preadipocytes to mature adipocytes [20, 21]. Fat tissue
derived adipocytes express several regulatory proteins such as
Wnts and 𝛽-catenin, which repress adipogenic differentiation
in preadipocytes [22, 23].
Obesity increases oxidative stress and concurrently
decreases expression and activity of key cytoprotective
enzyme systems, including heme oxygenase-1 (HO-1) [24,
25]. Heme oxygenase-1 is a stress-response protein and
decreased expression results in an increase in cellular heme
content, resulting in oxidative stress and adipocyte dys-
function [7, 26]. Induction of HO-1 decreases endogenous
ROS and the protective effect of increased HO-1 expression
is ascribed to several factors that include a reduction in
cellular heme, the induction of the iron binding protein,
ferritin, and the increased formation of bilirubin, which
efficiently scavenges toxic oxygen species [7]. Induction of
HO-1 expression in vivo and in vitro is associated with
an increase in preadipocytes, a reduction in the number
of enlarged adipocytes, elevated adiponectin secretion, and
an increase in the number of small adipocytes, which are
regarded as “healthy” adipocytes [27–31]. More importantly,
heterozygous HO-1 knockout mice treated with an inducer
of HO-1 failed to increase the production of nitric oxide
[32]. Improvement in nitric oxide bioavailability and vascular
function are critical to arterial induction of HO-1 [32].
The goal of this study was to determine the role of
HO-1 gene expression in the fructose-mediated increase in
adiposity, inflammation, andmetabolic imbalance, in in vitro
and in vivomodels of excessive fructose intake.This is the first
study to demonstrate that increased expression of HO-1 plays
a significant role in modulating the phenotype of adipocytes
via a decrease in heme and isoprostane levels inMSC-derived
adipocytes treated with fructose and mice fed a high fructose
diet.
2. Materials and Methods
2.1. Experimental Design for In Vitro Experiment
2.1.1. Human Bone Marrow-Derived MSC Culture. Frozen
bone marrow mononuclear cells were purchased from All-
cells (Emeryville, CA). After thawing, mononuclear cells
(MSCs) were resuspended in 𝛼-minimal essential medium
(𝛼-MEM, Invitrogen, Carlsbad, CA) that was supplemented
with 20% FBS and 1% A/A. The cells were transferred into
a 75 cm2 flask, cultured in 𝛼-MEM with supplements, and
maintained at 37∘C in a 5% CO
2
incubator. Medium was
changed after 24 hours and every 2 days thereafter. Once 80%
confluent, the MSCs were recovered by the addition of 0.25%
trypsin/EDTA, split, and partitioned into additional 75 cm2
flasks.
2.1.2. Human Bone Marrow-Derived MSC Adipocyte Dif-
ferentiation. MSCs (passage 2-3) were plated in 75 cm2
flasks at a density of 1-2 × 104 cells per cm2 and were
again cultured in their respective maintenance media until
cells were 80% confluent. The maintenance medium was
then replaced with adipogenic medium and the cells were
cultured for an additional 14 days. The adipogenic medium
consisted of complete culture medium supplemented with
DMEM (Invitrogen, Carlsbad, CA), 10% FBS, 1% A/A,
10 𝜇g/mL insulin, 1 𝜇M dexamethasone (Sigma-Aldrich, St.
Louis, MO), and 0.1mM indomethacin (Sigma-Aldrich, St.
Louis, MO). Human MSCs were cultured in this adipogenic
differentiation medium along with fructose in the presence
and absence of the HO-1 inducer, cobalt protoporphyrin
(CoPP) (5𝜇M), and the HO activity inhibitor, tin (Sn4+)-
mesoporphyrin (SnMP) (5 𝜇M). Medium and treatments
were renewed daily. Concurrently, human bone marrow-
derived MSCs were plated in 24-well plates at a density
of 1 × 104 cells per cm2 and maintained for 24 hours in
their respective maintenance media. Following this initial 24
hours, cells were treated with the aforementioned adipogenic
differentiation medium in conjunction with fructose in the
presence and absence of CoPP (5𝜇M) and SnMP (5 𝜇M) for
14 days. MTT assay was done to determine the influence of
all treatments on cell viability and no significant change was
seen between the groups (data not shown).
2.2. Experimental Design for In Vivo Experiment. All animal
studies were approved by the Marshall University Animal
Care and Use Committee in accordance with the National
Institutes of Health Guidelines for Care and Use of Lab-
oratory Animals. Forty eight-week-old C57Bl6 male mice
were used in the studies. Mice were divided into 4 groups:
6 mice/group, control animals, mice fed a high fructose diet,
andmice fed a high fructose diet and treatedwithCoPP, in the
absence or presence of SnMP. Mice were fed either a normal
chow diet containing 11% fat, 62% carbohydrate, and 27.0%
protein with total calories of 12.6 KJ/g or a high fructose diet
containing 60% fructose, 13.6% starch, 7% total fat, and 19.4%
protein.The mice had free access to water. After four months
of high fructose diet, the average weight of the fructose group
showed a 1.4-fold increase in body weight compared to con-
trol animals. Administration of CoPP reversed the effect of
fructose to the levels of animals fed regular chow (2mg/100 g
body weight) (4mg/100 g bodyweight for the last month).
Concurrent administration of SnMP resulted in an increase
in body weight compared tomice fed fructose diets alone.We
monitored food intake in mice receiving a normal chow diet
or a high fructose diet and food intake did not change in any
treatment group including those administered CoPP-SnMP.
Blood samples were collected in K
3
EDTA tubes at sacrifice
and the plasma was separated. Samples were flash frozen in
liquid nitrogen and maintained at −80∘C until assayed.
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2.3. Effect of Varying Fructose Concentrations on Adipogenesis.
To determine the optimal effect of fructose on MSC-derived
adipocyte differentiation, cells were treated with fructose at
concentrations of 5, 50, and 500 𝜇M. After 14 days, cells were
stained with Oil Red O solution. Optimum concentration for
fructose was found to be 500 𝜇M and this concentration was
utilized during treatment of cells throughout the experimen-
tation.
2.4. Oil Red O Staining. 0.21%Oil RedO in 100% isopropanol
(Sigma Aldrich, St. Louis, MO) was used for staining. Briefly,
adipocytes were fixed in 4% formaldehyde, stained with Oil
RedO for 10min, and rinsedwith pH7.2 PBS (1x) (Invitrogen,
Carlsbad, CA). Pictures were captured using an Olympus
IX81motorized invertedmicroscope. Oil RedOwas eluted by
adding 100% isopropanol for 10min andODwasmeasured at
490 nm 24 hours later.
2.5. Measurement of Lipid Droplet Size. Cell size was mea-
sured using ImagePro Analyzer (Media Cybernetics, Inc.,
MD).The classification of the size of lipid droplets was based
on size by area (pixels).
2.6. Detection of Isoprostane, Heme, and Cytokine Levels for
In Vitro and In Vivo Experiments. Isoprostane levels were
determined in conditionedmedia and inmouse plasma using
an ELISA assay (Cayman Chemical, Ann Arbor, MI). Heme
content in MSCs and mouse adipose tissue was determined
by the pyridine hemochromogen method as described pre-
viously [33, 34]. The absorbance difference between 𝜆 557
and 𝜆 530 nm was used to calculate hepatic heme using an
extinction coefficient of 20.7mM−1 cm−2. TNF𝛼, IL-1𝛽, and
IL-6 levels were determined in conditionedmedia andmouse
serum using an ELISA assay (Pierce Biotechnology, Woburn,
MA).
2.7. Preparation of Adipocyte Matrix from Adipose Tissues
Using Collagenase. Subcutaneous and visceral fat visible in
the abdomen mesenteric fat, fat around the liver, kidney, and
spleen was dissected free at the time of sacrifice and used to
extract fat cells for RNA. Fat tissue wasminced and incubated
in 20mL of Hank’s balanced salt solution (HBSS) 1x (without
calcium or magnesium), buffer containing 1% BSA and 0.1%
collagenase at 1-2 gm of fat/10mL.The fat tissues were placed
in 15mL conical tubes containing RNA inhibitors for RNA
extraction and incubated in a warmwater bath for 2 minutes.
Wash fat in 3 serial dilutions of Betadine solution in PBS and
then mince fat with sterile scissors for 2-3 minutes followed
by RNA.
2.8. RNA Extraction and Real-Time PCR for In Vitro and
In Vivo Experiments. Total RNA was extracted from mice
adipose tissue using RNeasy Protect Mini kit (QIAGEN,
Maryland, USA) according to manufacturer’s instructions.
Total RNA (1 𝜇g) was transcribed into cDNAusingGeneAmp
kit (Applied Biosystems, Branchburg, NJ, USA) reverse tran-
scription reagents. Total RNA was analyzed by a quantitative
real-time polymerase chain reaction (qRT-PCR). Real-time
PCR was performed using SYBR Green PCR Master Mix
(Applied Biosystems) on a 7500 HT Fast Real-Time PCR
System (Applied Biosystems). Specific primers for human
MSCs were the following, with actin being used as an
endogenous control described in Table 1. Specific primers for
mouse tissue were as in Table 1, with actin being used as an
endogenous control.
2.9. Statistical Analyses. Statistical significance was deter-
mined using one-way analysis of variance followed by Tukey-
Kramer post hoc test. 𝑃 < 0.05 was considered to be
significant. Data are expressed as means ± SEM.
3. Results
3.1. Fructose Increases Adipogenesis and Isoprostane Release in
a Dose-Dependent Manner in MSCs. In order to determine
the optimal concentration for adipocyte differentiation in
cultured human MSCs, cells were treated with fructose, 5,
50, and 500 𝜇M. This resulted in an increase in large lipid
droplets in MSCs and a decrease in small lipid droplets in
a dose-dependent manner (Figures 1(a) and 1(b)). 500 𝜇M
of fructose was determined to be the optimal concentration
for stimulating adipogenesis (𝑃 < 0.05 versus control)
(Figures 1(a) and 1(b)). Isoprostane levels increased in a dose-
dependent manner in conditional media of cultured MSCs,
with 50 and 500 𝜇M, the concentration at which there was
the significant increase in isoprostane levels compared to
control as determined by ELISA (Figure 1(c), 𝑃 < 0.05 versus
control).
3.2. Isoprostane Release and Heme Content Increase during
Adipogenesis. We examined if a relationship with adipogene-
sis and isoprostane and cellular heme levels existed in MSCs.
We observed a significant increase in isoprostane levels from
day 0 to day 14 (Figure 2(a)) along with an increase in cellular
heme content (Figure 2(b)). These results show, for the first
time, an increase in isoprostane production andheme content
with fructose-mediated adipogenesis.
3.3. HO-1 Overexpression Attenuates Fructose-Mediated Adi-
pogenesis and Lipid Accumulation. In order to examine the
effect of overexpression of HO-1 on adipogenesis, we treated
cells with CoPP with or without SnMP in the presence of
500𝜇M fructose (Figure 3). After 14 days, the number of lipid
droplets stained with Oil Red O was lower after CoPP when
compared to control (Figure 3(a), 𝑃 < 0.05). In contrast,
SnMP resulted in higher levels of Oil Red O staining when
compared to control (𝑃 < 0.05). CoPP decreased the number
of large lipid droplets and increased the number of small lipid
droplets when compared to control (Figures 3(b) and 3(c),
𝑃 < 0.05). SnMP reversed these effects when compared to
both CoPP and control (𝑃 < 0.05).
3.4. HO-1 Overexpression Reduces Isoprostane Production and
Adipogenic Marker Expression and Concurrently Increases
Canonical Wnt Signaling in Human MSCs. To verify that
fructose-mediated adipocyte dysfunction can be reversed via
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Table 1: The sequence of primers used for real-time PCR.
Primer Forward Reverse
Actin 5󸀠-AGGCACCAGGGCGTGAT-3󸀠 5󸀠-GCCCACATAGGAATCCTTCTGAC-3󸀠
HO-1 5󸀠-TGAAGGAGGCCACCAAGGAG-3󸀠 5󸀠-CCCCTGAGAGGTCACCCAGG-3󸀠
Mest 5󸀠-CCAGCACATCCCGGTGCTT-3󸀠 5󸀠-TTCCATGAGTGCAGAGCAGG-3󸀠
𝛽-Catenin 5󸀠-GGCAGGATACACGGTGCCGC-3󸀠 5󸀠-CTTCAGGTACCCTCAGGCCCGC-3󸀠
Wnt10b 5󸀠-GGTCTCGGCCTCCGCCCTTA-3󸀠 5󸀠-ACGGAAACCGCGCTTGAGGA-3󸀠
Adiponectin 5󸀠-GACGACACCAAAAGGGCTCAGG-3󸀠 5󸀠-CATCACGGCCTGGTGTGCCA-3󸀠
aP2 5󸀠-TGATGCCTTTGTGGGAACCT-3󸀠 5󸀠-GCAAAGCCCACTCCCACTT-3󸀠
FAS 5󸀠-GGACATGGTCACAGACGATGAC-3󸀠 5󸀠-GTCGAACTTGGACAGATCCTTCA-3󸀠
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Figure 1: (a) Number of large lipid droplets from Oil Red O stained MSCs with 0, 5, 50, or 500 𝜇M of fructose, magnifications: 40x (𝑛 = 3),
and (b) number of small lipid droplets from Oil Red O stained MSCs with 0, 5, 50, or 500 𝜇M of fructose, magnifications: 40x (𝑛 = 3). A
representative section for each group is shown. (c) Measurement of isoprostane levels in conditioned media of differentiating MSCs. Values
represent means ± SEM of five independent treatments. ∗𝑃 < 0.05 versus control or #𝑃 < 0.05 versus Fr 5 𝜇M or +𝑃 < 0.05 versus Fr 50 𝜇M.
overexpression of HO-1, we measured the expression of HO-
1 and adiponectin in pelleted cells, along with isoprostane
and IL-6 levels in collected conditioned media after 14 days.
Fructose treatment decreased the levels of both HO-1 and
adiponectin compared to control (Figures 4(a) and 4(b),
𝑃 < 0.05). Parallel to this finding, isoprostane and IL-6
levels in cells treated with fructose increased compared to
control (Figures 4(c) and 4(d), 𝑃 < 0.05). CoPP produced
an increase in HO-1 and adiponectin expression compared
to fructose alone (𝑃 < 0.05). There was a concomitant
decrease in isoprostane and IL-6 levels compared to the
fructose group (𝑃 < 0.05). SnMP reversed the effect of CoPP,
suggesting a regulatory role of HO activity in attenuating
fructose-mediated adipocyte damage. We then measured
mRNA levels of the canonical Wnt signaling molecules 𝛽-
catenin andWnt10b, alongwith aP2 and Peg-1/Mest. Fructose
decreased the expression of 𝛽-catenin andWnt10b in pelleted
cells compared to control (Figures 5(a) and 5(b), resp., 𝑃 <
0.05) and increased the expression of aP2 and Peg-1/Mest
compared to control (Figures 5(c) and 5(d), 𝑃 < 0.05). CoPP
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Figure 2: Measurement of 8-isoprostane in conditioned media and heme content in pelleted cells at days 0, 7, 10, and 14 of adipogenesis in
human MSCs treated with 500 𝜇M fructose (Figures 2(a) and 2(b), resp.). Values represent means ± SEM of five independent treatments.
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Figure 3: (a) Adipogenesis as shown by Oil Red O staining in MSCs treated with 500𝜇M fructose with or without CoPP, in the presence or
absence of SnMP, magnifications and lipid droplet size from Oil Red O stained MSCs: 40x (𝑛 = 3). A representative section for each group is
shown. (b) Number of large lipid droplets from Oil Red O stained MSCs treated with 500 𝜇M fructose with or without CoPP, in the presence
or absence of SnMP. (c) Number of small lipid droplets from Oil Red O treated with 500 𝜇M fructose with or without CoPP, in the presence
or absence of SnMP. Values represent means ± SEM of five independent treatments. ∗𝑃 < 0.05 versus control or #𝑃 < 0.05 versus fructose or
+
𝑃 < 0.05 versus fructose + CoPP.
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Figure 4: (a) Real-time PCR of HO-1 expression; (b) adiponectin expression; (c) concentration of 8-isoprostane in MSCs separated into
control, fructose, fructose treated with CoPP, and fructose treated with CoPP and SnMP; and (d) concentration of IL-6 in conditionedmedia.
Values represent means ± SEM of five independent treatments. ∗𝑃 < 0.05 versus control or #𝑃 < 0.05 versus fructose or +𝑃 < 0.05 versus
fructose with CoPP.
increased expression of 𝛽-catenin and Wnt10b compared
to fructose treatment (𝑃 < 0.05) while simultaneously
decreasing the expression of aP2 and Peg-1/Mest compared to
the fructose group (𝑃 < 0.05). The beneficial effect of CoPP
was reversed by concurrent treatment with SnMP (𝑃 < 0.05).
3.5. High Fructose Diet Increases Adipose Heme Content
and Serum Isoprostane Levels In Vivo. Adipose tissue heme
content increased compared to control in animals fed a high
fructose diet (Figure 6, 𝑃 < 0.05). CoPP ameliorated this
increase (𝑃 < 0.05) and the concurrent administration of
SnMP reversed the effects of CoPP (𝑃 < 0.05). Isoprostane
levels in plasma were increased in animals fed a high fructose
diet (Figure 7(a), 𝑃 < 0.05 versus control); however, CoPP
decreased isoprostane levels (𝑃 < 0.05); SnMP attenuated
the beneficial effect of CoPP (𝑃 < 0.05). TNF𝛼, IL-1, and
IL-6 serum levels increased compared to control in mice
fed a high fructose diet (Figures 7(b)–7(d), 𝑃 < 0.05).
CoPP ameliorated this increase in inflammatory cytokines
(𝑃 < 0.05) to levels below control and the concurrent
administration of SnMP reversed the effects of CoPP (𝑃 <
0.05). These findings support HO-1 as a key regulatory
factor in reducing fructose-mediated increases in heme and
isoprostane production in vivo.
3.6. HO-1 Overexpression Ameliorates Fructose-Mediated Ad-
iposity and Adipocyte Dysfunction In Vivo. HO-1, adiponect-
in, and the adipogenic markers fatty acid synthase (FAS)
and aP2 were measured in adipose tissue. A fructose diet
decreased the levels of HO-1 and adiponectin compared to
animals fed a normal chow diet (Figures 8(a) and 8(b), 𝑃 <
0.05). Mice fed a high fructose diet exhibited a concurrent
increase in FAS and aP2 gene expression in adipose tissue
compared to mice fed a normal chow diet (Figures 8(c) and
8(d), 𝑃 < 0.05). CoPP increased HO-1 and adiponectin
expression compared to both the control and fructose groups
(𝑃 < 0.05) and decreased the levels of FAS and aP2 compared
to the fructose group (𝑃 < 0.05). In contrast, SnMP reversed
the beneficial effects of CoPP (𝑃 < 0.05).
4. Discussion
This is the first study to show that upregulation of HO-
1 gene expression decreased fructose-mediated isoprostane
and heme levels inMSC-derived adipocytes and inmice fed a
high fructose diet, thereby decreasing adipocyte dysfunction.
These findings are associated with decreased inflammatory
cytokine levels, increased adiponectin, and the elevated
expression of genes of the canonical Wnt signaling cascade.
Thus, the upregulation ofHO-1may provide a potential target
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Figure 5: (a) Real-time PCR of 𝛽-catenin; (b) Wnt10b; (c) aP2; and (d) Peg-1/Mest expression in MSCs separated into control, fructose,
fructose treated with CoPP, and fructose treated with CoPP and SnMP. Values represent means ± SEM of five independent treatments. ∗𝑃 <
0.05 versus control or #𝑃 < 0.05 versus fructose or +𝑃 < 0.05 versus fructose with CoPP.
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Figure 6: Cellular heme content from adipose tissue in mice fed
chow diet, high fructose diet, and high fructose diet treated with
CoPP, in the presence or absence of SnMP. Values represent means
± SEM of four independent mice per group. ∗𝑃 < 0.05 versus chow
diet or #𝑃 < 0.05 versus high fructose diet or +𝑃 < 0.05 versus high
fructose with CoPP.
for pharmacological intervention in the treatment of patients
with diet-induced obesity and metabolic syndrome without
side effect. Mechanisms that govern metabolic adaptation
to food intake during CoPP-mediated increase in HO-1
induced weight loss are not well understood. The loss of
fat suggests that CoPP treated animals preferably used fatty
acid as energy sources during weight loss. Weight loss with
a normal appetite is a common specific response that is well
documented [35–38].
The increased expression of HO-1 resulted in decreased
isoprostane levels in fructose-mediated adiposity both in
vitro and in vivo,whereas inhibition of HO activity, by SnMP,
increased adipocyte differentiation and isoprostane produc-
tion.Theperturbations in isoprostane levels and adipogenesis
as a result of modulation of HO-1 levels are in part related
to adipose heme content. Heme, a known prooxidant, con-
tributes to the generation of ROS [9] and increased amounts
of heme cause stem cell differentiation and the release of
inflammatory cytokines [26, 39–41]. In concordance with
previous reports, our results show that the increase in cellular
heme appears to constitute a major factor in the fructose-
mediated isoprostane release, the increase in oxidative stress,
and adipocyte dysfunction.Our results suggest that one of the
mechanisms bywhichHO-1modulation affects adiposity and
decreases isoprostane levels is via the control of the cellular
heme pool. We have previously shown that CoPP increased
HO-1 protein expression in the adipocyte, in adipose tissue
of human MSC-derived adipocytes, and in mice fed high
fat diets [25, 42]. CoPP, through the induction of HO-1,
attenuated the “molecular switch” of isoprostane and heme to
genetically reprogram the adipocyte phenotype and prevent
fructose-mediated adiposity and adipocyte dysfunction.
Fructose bypasses the two highly regulated steps of
glycolysis, catalyzed by glucokinase/hexokinase and phos-
phofructokinase. Instead, fructose enters the pathway at a
level that is not regulated and excessive fructose metabolism
leads to the direct activation of ROS throughNADPHoxidase
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Figure 7: Assay of plasma concentrations of (a) isoprostane, (b) TNF𝛼, (c) IL-1, and (d) IL-6 in mice fed chow diet or high fructose diet and
high fructose diet treated with CoPP, in the presence or absence of SnMP. Values represent means ± SEM of four independent mice per group.
∗
𝑃 < 0.05 versus chow diet or #𝑃 < 0.05 versus high fructose diet or +𝑃 < 0.05 versus high fructose with CoPP.
[43]. Uncontrolled fructose metabolism leads to postpran-
dial hypertriglyceridemia, which increases ROS. Previous
findings have shown that obesity and ROS decreased HO-
1 expression [24, 25]. Elevated glucose levels decrease HO-1
expression [44, 45] analogous to what is observed in humans
and rodents with obesity. In concordance with these findings,
our results show that MSC-derived adipocytes treated with
fructose and mice fed a high fructose diet resulted in
diminished HO-1 expression.
Further, our results show that isoprostane levels increased
in a dose-dependent manner with fructose treatment in
MSCs-derived adipocytes and in mice fed a high fructose
diet. The increase in isoprostanes was associated with a
decrease in HO-1 expression and an increase in heme lev-
els. Isoprostanes and heme are regarded as valid markers
of oxidative stress [8, 10, 46, 47]. Isoprostane production
increases in experimental models of diabetes and metabolic
syndrome and is ameliorated by the induction of HO-1 [8, 46,
48]. Polyphenol derived diets prevent vascular dysfunction
and increase nitric oxide associated with arterial induction of
HO-1 [32]. Here, we show, for the first time, that isoprostane
production is increased in MSCs treated with fructose in
a dose-dependent manner and in mice fed a high fructose
diet and that CoPP reverses this effect thus suggesting a
potentialmechanismbywhich fructosemay lead to adipocyte
dysfunction in obesity.
Several key findings in this report offer potential insights
into how increased HO-1 expression resulted in decreased
levels of fructose-mediated adipogenesis and obesity. Firstly,
our in vitro and in vivo studies show that an increase in
HO-1 gene expression resulted in an increase in adiponectin
levels in the presence of excessive fructose intake. In addition,
upregulation of HO-1 decreased serum isoprostane and
heme content, while simultaneously diminishing the levels of
inflammatory cytokines. It is noteworthy that heme levels are
increased during adipogenesis [26, 49] while HO-1 protein
levels and HO activity are decreased in models of obesity
and metabolic syndrome [24, 27, 28]. Another mechanism
by which upregulation of HO-1 may decrease adiposity is
related to an increase in the level of CO and bilirubin, the
latter being a potent antioxidant. Bilirubin has been shown
to scavenge ROS [50, 51] and play a role in the inhibition
of NADPH oxidase [52] and protein kinase C (PKC) [53],
which are key modulators of oxidant-induced adipocyte
dysfunction. Inhibition of biliverdin reductase, the enzyme
that converts biliverdin to bilirubin, and the consequent
decrease in bilirubin production increase ROS 3-fold [54].
Therefore, increased levels of bilirubin may play a significant
role in decreasing oxidants in adiposity.
Another potential mechanism via which upregulation of
HO-1 decreases adipocyte hypertrophy may be the activa-
tion of the canonical Wnt pathway. HO-1 acts upstream of
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Figure 8: (a) Real-time PCR of HO-1, (b) adiponectin, (c) FAS, and (d) aP2 expression in chow diet, high fructose diet, and fructose diet
treated with CoPP, in the presence or absence of SnMP. Values represent means ± SEM of five independent treatments. ∗𝑃 < 0.05 versus chow
diet or #𝑃 < 0.05 versus high fructose diet or +𝑃 < 0.05 versus high fructose with CoPP.
the canonical Wnt cascade and decreases lipogenesis and
adipocyte differentiation in MSCs [55]. Wnts regulate gene
expression through either the canonical (𝛽-catenin depen-
dent) or the noncanonical pathway (𝛽-catenin independent)
[22, 23]. An increase in Wnt/𝛽-catenin signaling inhibits the
adipogenic transcription factors C/EBP𝛼 and PPAR𝛾 [56, 57].
C/EBP𝛼 and PPAR𝛼 are central to growth arrest, that is, a
prerequisite for adipocyte differentiation. Additionally, Peg-
1/Mest upregulation results in the enlargement of adipocytes
during adipose tissue expansion. On accumulation of triglyc-
erides, Peg-1/Mest levels are increased with a parallel signal
to preadipocytes to enlarge in order to accommodate more
triglycerides [58]. Adipocyte enlargement is associated with
an increase in the levels of inflammatory cytokines and
oxidative stress [27, 30, 59].
Our results show that the increase in HO-1 gene expres-
sion resulted in an increase in the canonical Wnt signaling
cascade and a decrease in Peg-1/Mest levels. A decrease
in Peg-1/Mest is beneficial in the control of obesity, since
upregulation of Peg-1/Mest occurs in obese adipose tissue
in several models of obesity [60, 61]. Our data demonstrate
that the overexpression of HO-1 was effective in suppressing
adipocyte differentiation, as evidenced by an increase in
the canonical Wnt cascade and a decrease in Peg-1/Mest.
These effects were reversed by SnMP, further demonstrating
that the HO-1-mediated increase in negative regulators of
adipogenesis and decrease in Peg-1/Mest resulted in the
attenuation of adipogenesis and lipid accumulation. Taken
together, these observations provide compelling evidence
that the HO-1-mediated increase in Wnt signaling pathway
modulates fructose-mediated adipogenesis.
A final mechanism by which CoPP-mediated upreg-
ulation of HO-1 and HO activity could decrease lipid
accumulation is through elevated levels of adiponectin. A
decrease in oxidative stress results in adipocytes secreting
more adiponectin [27]. Thus, adiponectin may be consid-
ered a therapeutic target for HO-1 in reducing fructose-
mediated adipocyte dysfunction and lipid accumulation, as
previous findings have shown that induction of HO-1 reduces
isoprostane and inflammatory cytokine levels through an
increase in adiponectin [29]. In contrast, inhibition of HO
activity decreased the expression of adiponectin confirming
that adipocyte hypertrophy results in a diminished secretion
of adiponectin [55]. Furthermore, increased heme levels, as a
result of reduced HO-1 expression and HO activity, decrease
adiponectin secretion from adipose tissue and increase
adipocyte dysfunction and inflammation [26]. Similarly, our
results show that upregulation of HO-1 in in vitro and in vivo
models of high fructose consumption resulted in an increase
in adiponectin levels along with a decrease in isoprostane and
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Figure 9: Schematic diagram of fructose-mediated adipocyte expansion and potential mechanisms underlyingHO-1-mediated improvement
of fructose-induced adipocyte hypertrophy. Excessive fructose consumption is accompanied by decreases in HO-1 gene expression and a
concurrent increase in cellular heme levels. Increase in cellular heme results in lipid peroxidation of the essential fatty acid, arachidonic acid,
via activation of ROS. The metabolite of this process is isoprostane and, therefore, heme catalyzes isoprostane synthesis. Isoprostane release
induces adipocyte hypertrophy and dysfunction. In contrast, the increase in HO-1 expression and HO activity by pharmacological agents, for
example, CoPP, leads to a decrease in the cellular heme pool and an increase in the canonical Wnt pathway and of adiponectin. Adiponectin
enhances the antioxidant mechanisms, thereby decreasing lipid droplet size along with attenuation of isoprostane production. An increase
in HO activity lowers lipid peroxidation, thereby decreasing isoprostane production and diminishing expression of the adipogenic markers
Peg-1/Mest, FAS, and aP2, resulting in the lowering of adipocyte hypertrophy. Thus, activation of the HO-1-adiponectin axis along with an
increase in the canonical Wnt cascade results in decreased heme (prooxidant) levels and isoprostane production in adipocytes and a decrease
in fructose-mediated adipocyte dysfunction and lipid accumulation.
heme levels. Thus, activation of the HO-1-adiponectin axis
may decrease fructose-mediated adipocyte dysfunction and
metabolic imbalance.
In summary, this study demonstrates that the phar-
macological induction of HO-1 results in a decrease in
heme and isoprostane levels and a reduction in fructose-
mediated adipocyte hypertrophy (as represented in Figure 9).
We demonstrate that the stimulatory effect of exogenous
fructose on isoprostane release exacerbates lipid accumula-
tion and adipocyte dysfunction in MSC-derived adipocytes
and mice fed a high fructose diet. Our results confirm the
proadipogenic effects of fructose and account for the positive
relationship between a high fructose diet and the presence of
obesity. This may prove crucial in the control of obesity and
the onset of metabolic syndrome as a result of a western high
fructose diet.
What is already known about this subject is as follows.
(i) Fructose consumption causes adiposity and increases
reactive oxygen species (ROS) levels.
(ii) Induction of heme oxygenase-1 (HO-1) decreases
adiposity.
(iii) Isoprostanes are a marker of oxidative stress.
What this study adds is as follows.
(i) Fructose-mediated increase in adipogenesis is asso-
ciated with an increase in isoprostane production in
stem cell-derived adipocyte (MSCs).
(ii) Fructose increases isoprostane production in a dose-
dependent manner.
(iii) Fructose increases the level of cellular heme, a proox-
idant, in adipose tissue and the release of isoprostane
into plasma.
(iv) An increase in HO-1 expression reduces obesity and
F2-isoprostane plasma levels inmice fed high fructose
diets.
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